Massive hope for pancreatic cancer pill after trial saw tumours vanish
A daily pill called daraxonrasib combined with chemotherapy made tumours undetectable in one in 12 patients with advanced pancreatic cancer in early trials, which Cancer Research UK called the biggest leap forward in decades.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Early trial results presented at the EORTC conference show that daraxonrasib, a KRAS inhibitor already approved in the US, combined with gemcitabine and nab-paclitaxel chemotherapy produced unprecedented responses in patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma. Among 61 participants, tumours became undetectable on CT scans in around 8% of patients, or one in 12, according to BBC reporting. Tumours stopped growing in almost all participants. The trial followed patients for a year and a half on average, and some did not see their cancer return during this period.
Dr Wungki Park from Memorial Sloan Kettering Cancer Center, who is involved in the trial, told the BBC the results were extremely encouraging: "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival." Cancer Research UK's Dr Sam Godfrey called it "the biggest leap forward in decades" for pancreatic cancer patients, adding: "What this new drug has done is it's found a way of drugging the undruggable. We are finally seeing progress in pancreatic cancer which is so long overdue."
Daraxonrasib works by locking on to and shutting off certain RAS mutations found in most pancreatic cancers that drive tumour growth. Dozens of other cancers, including lung and ovarian, can have similar mutations, meaning the drug might help many other patients. Dr Godfrey said: "I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers." Prof Elena Garralda, chair of the EORTC conference, said the combined treatment could potentially significantly improve patients' overall survival and the time before tumours start to grow again.
Doctors stress it is a long way from knowing how long the treatment might keep the disease at bay and it should not be seen as a cure. Dr Godfrey cautioned: "Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed." Longer studies are needed to understand if any cancers can be put into remission and for how long. Pancreatic cancer has the lowest survival rate of all common cancers in the UK, with 11,500 diagnoses and around 10,200 deaths each year according to Cancer Research UK.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 2h ago.
Quick answers
What is daraxonrasib and how does it work?
Daraxonrasib is a KRAS inhibitor that works by locking on to and shutting off certain RAS mutations found in most pancreatic cancers that drive tumour growth. It is taken as a daily pill and has already been approved in the US.
What were the key results from the trial?
In a trial of 61 patients with newly diagnosed metastatic pancreatic cancer, tumours became undetectable on CT scans in around 8% of patients (one in 12), and tumours stopped growing in almost all participants. The trial followed patients for a year and a half on average.
Is this considered a cure for pancreatic cancer?
No. Doctors stress it is a long way from knowing how long the treatment might keep the disease at bay and it should not be seen as a cure. Longer studies are needed to understand if any cancers can be put into remission and for how long.
Coverage (7)
- Metastatic pancreatic cancer responds well to initial treatment with combination of daraxonrasib and chemotherapy EurekAlert! · 6h ago
- Interpreting Subgroup Analyses OncLive · 6h ago
- Oral therapy wins approval in Europe for already-treated metastatic PDAC Rare Cancer News · 6h ago
- Revolution Medicines Reports Encouraging Updated Phase 1/2 Data for RASONQUE Plus Gemcitabine and Nab-Paclitaxel in First-Line Metastatic Pancreatic Cancer Quiver Quantitative · 6h ago
- Daraxonrasib Chemotherapy Combination Shows Promising Tumour Shrinkage in Metastatic Pancreatic Cancer Trial Bioengineer.org · 6h ago
- ‘Game-changing’ pancreatic cancer drug can make tumours vanish The Times · 6h ago
- Massive hope for pancreatic cancer pill after trial saw tumours vanish BBC · 6h ago
Topics
Related trends
Pancreatic cancer mystery deepens as researchers make unexpected discovery
Recent studies reveal unexpected biological differences and immune cell behaviors in pancreatic cancer.
NHS England on track to miss key cancer treatment target by 10,000 patients
NHS England is projected to miss its 2027 cancer treatment target by approximately 10,000 patients, according to multiple outlets reporting on the latest waiting-time data.
Richard Sterban, the Bass Singer for the Oak Ridge Boys, Dies at 83
Richard Sterban, the distinctive bass singer of the legendary country and gospel group The Oak Ridge Boys, has died at 83.
Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory
MedPacto reported that its experimental drug MP010 eliminated 75% to 87.5% of aggressive pancreatic tumors in mice.
Strong immune system can prevent prostate cancer, Oxford study finds
An Oxford study links stronger immune activity to lower prostate cancer risk, drawing coverage across research, health and mainstream outlets.
Gastroenterologist Warns: Indigestion After Meals May Signal Early Pancreatic Cancer
A gastroenterologist's warning that post-meal indigestion could signal early pancreatic cancer is driving a wave of awareness coverage across U.S. and Australian outlets.